Healthcare
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestonesHUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today
About this update from Lifeward Ltd.
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that it has entered into a securities purchase agreement with a group of institutional and accredited investors participating in the strategic financing framework established earlier this year with Oramed Pharmaceuticals (Nasdaq: ORMP). "This financing reflects confidence in our strategy and the opportunity ahead," said Mark Grant, President and Chief Executive Officer of Lifeward. "We have built the clinical evidence, reimbursement infrastructure and commercial foundation needed to scale our business. This additional capital strengthens our ability to accelerate the commercialization of our restorative healthcare platform, including expansion of our reimbursement-backed distribution model, and advancement of our product portfolio." The initial closing, which took place on July 6, 2026, consists of approximately $5.6 million of senior secured convertible notes and accompanying warrants. The investors have also committed to purchase an additional $5.6 million of notes and warrants upon the achievement of predefined commercial milestones, including either: The milestone-based structure aligns additional capital with commercial execution and shareholder value creation. This financing is in addition to, and expands upon, the strategic capital framework established through Lifeward's partnership with Oramed, which provides the Company with access to up to $47 million in financing, the first $10 million of which has been funded to date. Additional information regarding the financing is included in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. About Lifeward Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company's established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity...